Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

PARP Combination Therapies: A New Horizon in Prostate Cancer Care
  • CME

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: March 30, 2022 Expiration: March 29, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Merck Sharp & Dohme Corp.
Pfizer, Inc.
Maha Hussain, MD, FACP, FASCO
Program Director
person default
Wassim Abida, MD, PhD
Heather H. Cheng, MD, PhD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select patients for treatment with currently approved PARP inhibitors by assessing DDR alterations
  • Effectively communicate to colleagues and patients the rationale for PARP inhibitor–based combinations in prostate cancer, in tumors with or without DDR alterations
  • Delineate the change in treatment sequence if phase III studies testing PARP inhibitor–based combinations for prostate cancer are positive
  • Manage adverse events associated with the use of PARP inhibitor combinations
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor combinations in prostate cancer

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Maha Hussain, MD, FACP, FASCO

Genevieve Teuton Professor of Medicine
Division of Hematology/Oncology
Deputy Director
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Maha Hussain, MD, FACP, FASCO, has disclosed that she has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, Merck, Novartis, Pfizer, and Tempus and funds for research support paid to her institution from Arvinas, AstraZeneca, Bayer, and Genentech.

Faculty

Wassim Abida, MD, PhD

Assistant Member
Assistant Attending Physician
Genitourinary Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Wassim Abida, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca/MedImmune, Clovis Oncology, Daiichi Sankyo, Janssen, ORIC, and Roche and funds for research support paid to his institution from AstraZeneca, Clovis Oncology, Epizyme, ORIC, and Zenith Epigenetics.
Heather H. Cheng, MD, PhD

Associate Professor
Department of Medicine (Oncology)
University of Washington
Division of Clinical Research
Fred Hutch Cancer Center
Seattle, Washington

Heather H. Cheng, MD, PhD, has disclosed that she has received consulting fees from AstraZeneca and funds for research support from Astellas, Clovis, Color Genomics, Janssen, Medivation, Phosplatin, and Sanofi.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Lisa Kuhns, PhD
Lisa Kuhns, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has disclosed that he had individual publicly traded stocks and stock options with AstraZeneca.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncologists and other healthcare professionals who care for patients with prostate cancer.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners to understand PARP inhibitor combination mechanisms and rationale and to integrate recent findings into the management of men with prostate cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 30, 2022, through March 29, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

PARP Combination Therapies: A New Horizon in Prostate Cancer Care
  • CME

Loading...
In this on-demand webcast of a live symposium, expert faculty discuss optimal use of PARP inhibitors in the clinic, guidance on genetic testing to select patients for this therapy, and the latest evidence on PARP inhibitor combinations to expand their benefit.
Maha Hussain, MD, FACP, FASCO
Program Director
person default
Wassim Abida, MD, PhD
Heather H. Cheng, MD, PhD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: March 30, 2022 Expiration: March 29, 2023

Related Content

Downloadable clinical resource with practical guidance on how to talk with your transgender patients about gender identity, including related terminology, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 30, 2022

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 28, 2022

Clinical Care Options (CCO): Dr Heather Cheng answers audience questions from a live symposium on current and expanding role of PARP inhibitors in prostate cancer care

Heather H. Cheng, MD, PhD Released: April 26, 2022

Clinical Care Options (CCO): Expert analysis from Drs. Daniel Petrylak and Toni Choueiri on key data in genitourinary cancers from ASCO GU 2022

Toni K. Choueiri, MD Daniel P. Petrylak, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 18, 2022 Expired: April 17, 2023
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Merck Sharp & Dohme Corp.
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings